On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Platform Demonstrates Excellent Results in Delivery of APIs to the Brain

Company: Lexaria Bioscience Corp. (LXRP)
Category: Stock Spotlights

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative delivery platform, DehydraTECH™, has demonstrated excellent results in delivery of nicotine to the brain in a recent lab study. An article discussing this reads, “The new report confirmed first generation results of in vivo tests on live animals showing that DehydraTECH™ was able to deliver more active pharmaceutical ingredients (APIs) across the brain’s protective blood brain barrier, as reported in an article published by the CFN Media Group (http://cnw.fm/0l9eM). Because of certain similarities in physical structure between the nicotine molecule and several of the drugs used to treat diseases such as Huntington’s, Parkinson’s, schizophrenia and depression, it is now theorized that DehydraTECH could offer similar delivery advantages.”

To view the full article, visit http://cnw.fm/LKw5v

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH™ delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com

More from CannabisNewsBreaks

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

Contact us: 303.498.7722